Department of Surgery, Cedars‑Sinai Medical Center, Los Angeles, CA 90048, USA.
Mol Med Rep. 2020 Dec;22(6):5003-5011. doi: 10.3892/mmr.2020.11627. Epub 2020 Oct 22.
The discovery, introduction and clinical use of prognostic and diagnostic biomarkers has significantly improved outcomes for patients with various illnesses, including bladder cancer (BC) and other bladder‑related diseases, such as benign bladder dysfunction and interstitial cystitis (IC). Several sensitive and noninvasive clinically relevant biomarkers for BC and IC have been identified. Metabolomic‑ and lipidomic‑based biomarkers have notable clinical potential in improving treatment outcomes for patients with cancer; however, there are also some noted limitations. This review article provides a short and concise summary of the literature on metabolomic and lipidomic biomarkers for BC and IC, focusing on the possible clinical utility of profiling metabolic alterations in BC and IC.
诊断和预后生物标志物的发现、引入和临床应用显著改善了各种疾病患者的预后，包括膀胱癌（BC）和其他与膀胱相关的疾病，如良性膀胱功能障碍和间质性膀胱炎（IC）。已经确定了几种用于 BC 和 IC 的敏感且非侵入性的临床相关生物标志物。代谢组学和脂质组学标志物在改善癌症患者的治疗效果方面具有显著的临床潜力；然而，也存在一些值得注意的局限性。本文简要综述了有关 BC 和 IC 的代谢组学和脂质组学生物标志物的文献，重点关注 BC 和 IC 代谢改变谱分析的可能临床应用。
